Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients

ConclusionComedications may be the cause for this inter-occasion variation in bioactivation of cyclophosphamide and the ensuing phenoconversion may account for the conflicting reports in the literature about the relationship betweenCYP2C19 genotype and CP bioactivation pharmacokinetics. Trial registration ANZCTR363222 (6/11/2012, retrospectively registered).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research